You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

Relvar: optimal size for absorption1,2

Asthma control is influenced by many factors and one often overlooked aspect is particle size.

Relvar’s particle size of 2.3–4.0 μm1 falls well within the optimal range for absorption of 1.0–5.0 μm.2

woman smiling in park woman smiling in park

There is no evidence that extra fine particles offer any additional clinically relevant benefits compared with standard ICS/LABA particle sizes.3

Relvar – molecules selected for their longer duration of action vs beclomethasone*4,5

Molecule Icon

Relvar is longer acting and more targeted to the appropriate receptors, compared with beclomethasone dipropionate (BDP)/formoterol (Form) (in vitro data)*4–6

Lungs Icon

Relvar provides significantly greater improvement in lung function vs BDP/Form at 12 months (99% vs 92% FEV1 predicted, p<0.01)7

Discover Relvar

woman staring

Defining asthma control

How do patient perceptions of asthma control differ from guideline definitions?

FIND OUT MORE
Woman staring out of window

Proactive asthma control

See how Relvar can help achieve asthma control

FIND OUT MORE
woman stretching

Safety

Read about the safety profile associated with Relvar

FIND OUT MORE
woman drinking from a bottle

Device

Discover the features and benefits of the Ellipta device

FIND OUT MORE

Need help with this product?

Request a contact

From a sales representatives

Stay informed

Get the latest updates from GSK

Footnotes

*In vitro data: clinical relevance is uncertain.

Abbreviations

BDP, beclomethasone dipropionate; FEV1, forced expiratory volume in one second; Form, formoterol; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist.

References
  1. GSK Data on File RF/FFT/0013/15(1); 2018.
  2. Scichilone N, et al. J Asthma Allergy 2013;6:11–21.
  3. El Baou C, et al. BMC Pulm Med 2017;17:31.
  4. Global Datasheet Fluticasone furoate/vilanterol: v11, March 2020.
  5. Rossios C, et al. Eur J Pharmacol 2011;670:244–251.
  6. Salter M, et al. Am J Physiol Lung Cell Mol Physiol 2007;293:L660–667.
  7. Dal Negro RW, et al. Multidiscip Respir Med 2018;13:18.

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

PM-IE-FFV-WCNT-230008 June 2023